Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Molecular Data stock price, quote, forecast and news

MKD
US60852L1061
A2PYCA

Price

0.01
Today +/-
+0
Today %
+0 %
P

Molecular Data stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Molecular Data stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Molecular Data stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Molecular Data stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Molecular Data's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Molecular Data Stock Price History

DateMolecular Data Price
11/4/20220.01 undefined
11/3/20220.01 undefined

Molecular Data Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Molecular Data, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Molecular Data from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Molecular Data’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Molecular Data. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Molecular Data’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Molecular Data’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Molecular Data’s growth potential.

Molecular Data Revenue, EBIT and net profit per share

DateMolecular Data RevenueMolecular Data EBITMolecular Data Net Income
20207.6 B undefined-331.56 M undefined-328 M undefined
201913.21 B undefined-192.21 M undefined-193.55 M undefined
20189.05 B undefined-235.79 M undefined-254.64 M undefined
20174.2 B undefined-89.73 M undefined-107.81 M undefined
20163.21 B undefined-105.77 M undefined-113.94 M undefined

Molecular Data Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20162017201820192020
3.214.29.0513.217.6
-31.04115.5045.89-42.49
0.811.190.880.76-0.13
265080100-10
-105-89-235-192-331
-3.28-2.12-2.60-1.45-4.36
-113-107-254-193-327
--5.31137.38-24.0269.43
23.0123.0123.0120.7123.21
-----
Details

Keystats

Revenue and Growth

The Molecular Data Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Molecular Data is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020
       
38.526.4815.16347.35
54.0343.121.257.11
47.1919.16189.984.94
19.27.264.352.82
217.52291.71256.17220.97
376.46367.7486.83663.19
2.651.764.334.92
60000353
0000
1.442.131.560.54
0000
00015.83
4.693.95.8921.63
381.15371.6492.72684.82
       
989898114
0.310.50.541.08
-305.71-560.35-753.9-1,081.91
00-0.32-21.19
0000
5.9-61.63-216.5-27.93
67.0149.32314.04334.15
36.5319.0138.8150.85
50.99159.16165.21146.57
138.570.0813.7533.75
6.7627.84143.96127.28
299.86255.42675.76692.61
75177.7833.4517.05
0000
0.390.0303
75.39177.8133.4520.05
375.25433.22709.21712.66
381.15371.6492.72684.73
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Molecular Data provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Molecular Data's financial health and stability.

Assets

Molecular Data's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Molecular Data must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Molecular Data after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Molecular Data's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020
-113-107-254-193-328
01231
0000-5
-43-96-81641
10161257856
81619411
00001,000
-145-186-134-95-234
-2-1-2-10
-2-3-2-1-320
0-200-320
00000
8183-2514920
0000492
17326237149529
9217963016
00000
2572-9951-46
-148.24-188.64-136.88-97.64-234.16
00000

Molecular Data stock margins

The Molecular Data margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Molecular Data. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Molecular Data.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Molecular Data's sales revenue. A higher gross margin percentage indicates that the Molecular Data retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Molecular Data's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Molecular Data's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Molecular Data's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Molecular Data. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Molecular Data's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Molecular Data Margin History

Molecular Data Gross marginMolecular Data Profit marginMolecular Data EBIT marginMolecular Data Profit margin
2020-0.13 %-4.36 %-4.32 %
20190.76 %-1.46 %-1.47 %
20180.89 %-2.6 %-2.81 %
20171.2 %-2.14 %-2.57 %
20160.81 %-3.3 %-3.55 %

Molecular Data Stock Sales Revenue, EBIT, Earnings per Share

The Molecular Data earnings per share therefore indicates how much revenue Molecular Data has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Molecular Data earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Molecular Data's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Molecular Data’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Molecular Data's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Molecular Data Revenue, EBIT and net profit per share

DateMolecular Data Sales per ShareMolecular Data EBIT per shareMolecular Data Earnings per Share
2020327.26 undefined-14.28 undefined-14.13 undefined
2019637.74 undefined-9.28 undefined-9.35 undefined
2018393.46 undefined-10.25 undefined-11.07 undefined
2017182.62 undefined-3.9 undefined-4.69 undefined
2016139.34 undefined-4.6 undefined-4.95 undefined

Molecular Data business model

Molecular Data Inc. is a leading technology company specializing in the use of big data, artificial intelligence (AI), and blockchain technology in the chemical and pharmaceutical industry. The company was founded in 2014 and is headquartered in Shanghai, China. Molecular Data Inc. has a comprehensive database consisting of millions of chemical compounds, which aids chemists, pharmaceutical companies, and researchers in identifying, exploring, and developing new drugs. The company places great importance on integrating data and technologies to accelerate and improve drug development. Molecular Data Inc. provides cloud-based solutions based on the analysis of big data through AI algorithms and blockchain technology. It offers platforms, as well as consulting and training services, to support customers in efficiently utilizing the platforms. The company's main products include the MDL platform, which enables the integration of data, knowledge, and algorithms to accelerate drug development processes. The MDL platform is a cloud-based system that provides access to a database of millions of compounds and allows users to receive real-time results. Molecular Data Inc. also offers a blockchain-based platform for the chemical and pharmaceutical industry, enhancing the transparency and security of data and information. The platform facilitates secure data exchange between different companies and regulatory authorities, providing improved control and monitoring of data. Another important service provided by Molecular Data Inc. is consulting and training for companies in implementing big data, AI, and blockchain into their workflows. The company aims to equip its customers with the necessary skills and knowledge to optimize their business processes and increase competitiveness. Molecular Data Inc. is divided into several divisions to ensure efficient collaboration and product development. These divisions include research and development, sales and marketing, finance and administration, and information technology. The company strives to expand its business through strategic partnerships and acquisitions. It has already completed several acquisitions to strengthen its expertise in big data, AI, and blockchain. Through these strategic measures, the company has been able to offer its customers a comprehensive range of products and services to enhance performance and increase competitiveness. Overall, Molecular Data Inc. is a significant company in the chemical and pharmaceutical industry that specializes in the integration of data and technologies to enhance process efficiency and speed. The company aims to strengthen its position as a market leader through innovation and strategic partnerships. Molecular Data is one of the most popular companies on Eulerpool.com.

Molecular Data SWOT Analysis

Strengths

Molecular Data Inc possesses a state-of-the-art technology infrastructure, allowing them to effectively store, process, and analyze large amounts of molecular data. This gives them a competitive advantage in the industry.

The company has a dedicated team of highly skilled researchers and scientists who continuously work on developing innovative solutions and improving their product offerings. This enables Molecular Data Inc to stay ahead in a rapidly evolving market.

Weaknesses

Molecular Data Inc currently has a limited market presence and brand recognition compared to some of its competitors. This may hinder their ability to attract new customers and expand their customer base.

The company heavily relies on external sources for obtaining molecular data, which introduces a certain level of dependency and potential risks. Any disruptions or limitations in accessing these sources could impact their operations.

Opportunities

The growing trend of precision medicine presents a significant opportunity for Molecular Data Inc. With its advanced technology and expertise, the company can cater to the increasing demand for personalized healthcare solutions.

Molecular Data Inc can explore and expand into new market segments, such as genomics, bioinformatics, or drug discovery. This diversification can help them tap into additional revenue streams and reduce reliance on a single market.

Threats

The molecular data industry is highly competitive, with several established players and new entrants. Molecular Data Inc faces the risk of losing market share to competitors offering similar products or services.

Compliance with evolving regulatory frameworks and intellectual property laws poses challenges for Molecular Data Inc's operations. Failure to comply can result in legal consequences and restrict their ability to operate in certain regions.

Molecular Data Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Molecular Data historical P/E ratio, EBIT, and P/S ratio.

Molecular Data shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Molecular Data earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Molecular Data's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Molecular Data’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Molecular Data's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Molecular Data Stock splits

In Molecular Data's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Molecular Data.

Molecular Data list of shareholders

%
Name
Stocks
Change
Date
7.34269 % Innovation Works Development Fund GP, L.L.C.805,020805,02012/31/2020
6.83900 % TB Alternative Assets Ltd.749,797643,4636/30/2022
0.20269 % Geode Capital Management, L.L.C.22,22203/31/2022
0.19199 % Virtu Americas LLC21,04921,0493/31/2022
0.18785 % Legacy Wealth Asset Management, LLC20,59520,5956/30/2022
0.10988 % Two Sigma Investments, LP12,04712,0473/31/2022
0.09897 % Susquehanna International Group, LLP10,85110,8513/31/2022
0.07036 % Citadel Advisors LLC7,7147,7143/31/2022
0.02433 % X-Square Capital, LLC2,6671,3343/31/2022
0.02433 % Buckingham Strategic Partners, LLC2,6672,6673/31/2022
1
2
3

Molecular Data Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,740,200,270,330,59-0,54
Koninklijke DSM Stock
Koninklijke DSM
SupplierCustomer0,650,560,680,780,03-0,71
SupplierCustomer0,450,060,140,66-0,51-0,59
SupplierCustomer0,320,400,780,74--0,74
SupplierCustomer0,280,11-0,340,30-0,29-0,18
SupplierCustomer0,120,440,470,710,48-0,40
SupplierCustomer0,100,49-0,300,460,73-0,21
SupplierCustomer0,07-0,28-0,300,470,23-0,28
SupplierCustomer0,010,300,760,580,600,13
SupplierCustomer-0,010,35-0,080,490,92-0,08
1
2

Most common questions regarding Molecular Data

What values and corporate philosophy does Molecular Data represent?

Molecular Data Inc represents values of innovation, collaboration, and excellence in the field of data-driven technology solutions. As a leading provider of integrated technology and marketing solutions, the company strives to empower businesses with reliable data insights and advanced technology applications to enhance their operational efficiency and decision-making capabilities. With a strong commitment to customer satisfaction and technical expertise, Molecular Data Inc aims to deliver customized solutions that meet the diverse business needs of its clients. Through continuous innovation and strategic partnerships, the company maintains a corporate philosophy focused on driving growth, harnessing technological advancements, and delivering long-term value to its stakeholders.

In which countries and regions is Molecular Data primarily present?

Molecular Data Inc is primarily present in China and serves various regions within the country. As a prominent player in the Chinese market, Molecular Data Inc operates nationwide, providing comprehensive services and solutions for the industrial chemical e-commerce sector. With its strong presence in China's chemical and life sciences industries, Molecular Data Inc has established a remarkable reputation and extensive network across different provinces and key economic regions. The company's focused presence in China allows it to cater to the specific demands of local industries effectively, ensuring reliable and efficient services for its clients.

What significant milestones has the company Molecular Data achieved?

Molecular Data Inc has achieved significant milestones since its establishment. The company has successfully positioned itself as a leading provider of integrated solutions for chemical e-commerce platforms in China. It has formed strategic partnerships with prominent chemical manufacturers, distributors, and e-commerce platforms. Molecular Data Inc has also established a network of suppliers, buyers, and logistics providers, enhancing its comprehensive supply chain management capabilities. Furthermore, the company has facilitated efficient procurement and distribution processes while promoting digital transformation in the chemical industry. These achievements reflect Molecular Data Inc's commitment to driving innovation, promoting collaboration, and delivering value-added solutions for its clients in the chemical sector.

What is the history and background of the company Molecular Data?

Molecular Data Inc is a company that specializes in providing data-driven integrated solutions for the chemical industry in China. Founded in 2001, the company has a rich history of leveraging big data analytics and advanced technologies to assist clients in optimizing their business decisions. With its vast industry expertise, Molecular Data Inc has become a trusted partner for chemical companies, offering comprehensive services including market intelligence, e-commerce solutions, and supply chain management. By continuously innovating and adapting to industry trends, the company has established itself as a leading player in China's chemical market. Molecular Data Inc's commitment to delivering high-quality data-driven solutions has earned it a strong reputation and position within the industry.

Who are the main competitors of Molecular Data in the market?

The main competitors of Molecular Data Inc in the market include companies such as Alibaba Group Holding Limited, JD.com, Inc., and Baozun Inc. These companies operate in the e-commerce and technology sectors, providing a range of services and solutions similar to Molecular Data Inc. While Alibaba Group Holding Limited is a dominant player in the Chinese e-commerce market, JD.com, Inc. focuses on online retailing. Baozun Inc. offers e-commerce solutions to various brand partners. As Molecular Data Inc operates in the same industry, these competitors pose potential challenges in terms of market share, customer acquisition, and revenue growth.

In which industries is Molecular Data primarily active?

Molecular Data Inc is primarily active in the industries of chemical and laboratory equipment, precision instruments, and scientific research services.

What is the business model of Molecular Data?

The business model of Molecular Data Inc focuses on providing chemical and pharmaceutical industries with integrated solutions. The company offers a comprehensive range of services including procurement, logistics, sales, regulatory compliance, and more. By leveraging its extensive network and industry expertise, Molecular Data Inc aims to facilitate efficient and cost-effective transactions between buyers and suppliers. The company's dedication to quality, reliability, and customer satisfaction has helped it become a trusted partner for businesses in the chemical and pharmaceutical sectors. With its strong market presence and commitment to innovation, Molecular Data Inc continues to drive growth and deliver value to its stakeholders.

What is the P/E ratio of Molecular Data 2024?

The P/E ratio cannot be calculated for Molecular Data at the moment.

What is the P/S ratio of Molecular Data 2024?

The P/S cannot be calculated for Molecular Data currently.

What is the AlleAktien quality score of Molecular Data?

The AlleAktien quality score for Molecular Data is 5/10.

What is the revenue of Molecular Data 2024?

The revenue cannot currently be calculated for Molecular Data.

How high is the profit of Molecular Data 2024?

The profit cannot currently be calculated for Molecular Data.

What is the business model of Molecular Data

Molecular Data Inc is a leading provider of data solutions and services for the biotech and pharmaceutical industry. The company helps its clients analyze and interpret complex biological data to gain new insights and make better decisions. The core business of Molecular Data is providing databases and analysis tools that enable researchers and scientists to process and understand genetic, proteomic, and chemical information. These databases include information on genes, proteins, metabolites, and drugs, allowing Molecular Data's customers to quickly and effectively find and utilize relevant information. One of the main divisions of Molecular Data is the development of software solutions for the biotech and pharmaceutical industry. The company offers a wide range of products, including databases for chemical compounds, genomes, and protein structures, as well as tools for data visualization and analysis. These solutions enable researchers to efficiently organize, analyze, and present their data, resulting in valuable insights. Another important area of Molecular Data is its services division. The company provides a variety of consulting services to help its clients achieve their research and development goals. These services include consulting on selecting the right instruments and technologies, developing protocols and procedures, providing support for data analysis, and training employees. Molecular Data also focuses on developing new technologies and tools that allow its customers to quickly respond to new developments and innovations in biotechnology and pharmaceuticals. This includes new algorithms, models, and simulations that enable researchers to understand and manipulate complex biological systems. These technologies are constantly being developed and improved to provide the best possible support to Molecular Data's customers. Overall, Molecular Data offers its customers a comprehensive portfolio of products and services tailored to the needs and requirements of the biotech and pharmaceutical industry. With its years of experience and expertise in data analysis and processing, the company is an important partner for researchers and scientists worldwide.

What is the Molecular Data dividend?

Molecular Data pays a dividend of 0 CNY distributed over payouts per year.

How often does Molecular Data pay dividends?

The dividend cannot currently be calculated for Molecular Data or the company does not pay out a dividend.

What is the Molecular Data ISIN?

The ISIN of Molecular Data is US60852L1061.

What is the Molecular Data WKN?

The WKN of Molecular Data is A2PYCA.

What is the Molecular Data ticker?

The ticker of Molecular Data is MKD.

How much dividend does Molecular Data pay?

Over the past 12 months, Molecular Data paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Molecular Data is expected to pay a dividend of 0 CNY.

What is the dividend yield of Molecular Data?

The current dividend yield of Molecular Data is .

When does Molecular Data pay dividends?

Molecular Data pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Molecular Data?

Molecular Data paid dividends every year for the past 0 years.

What is the dividend of Molecular Data?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Molecular Data located?

Molecular Data is assigned to the 'Cyclical consumption' sector.

Wann musste ich die Aktien von Molecular Data kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Molecular Data from 9/9/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Molecular Data pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Molecular Data in the year 2023?

In the year 2023, Molecular Data distributed 0 CNY as dividends.

In which currency does Molecular Data pay out the dividend?

The dividends of Molecular Data are distributed in CNY.

All fundamentals about Molecular Data

Our stock analysis for Molecular Data Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Data Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.